Vivani’s Cortigent to merge into ClearOne in Oct 2026
Vivani Medical discloses under Regulation FD that it expects the Cortigent–ClearOne merger transaction to price and close in October 2026, subject to customary risks.
Rhea-AI Filing Summary
Vivani Medical, Inc. (VANI) reports under Regulation FD that it has a definitive agreement and plan of merger involving its wholly owned subsidiary Cortigent, Inc., ClearOne, Inc., and CLRO Merger Sub, Inc., under which Cortigent will merge with and into Merger Sub and become a wholly owned subsidiary of ClearOne (the Transaction).
Vivani states that it currently anticipates the pricing and closing of the Transaction will occur in October 2026. The company characterizes related statements as forward-looking and highlights that risks, including an inability to consummate the Transaction, are discussed in its annual and quarterly reports filed with the SEC.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Item 7.01 — Regulation FD Disclosure
1 item
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Key Figures
Anticipated Transaction timing: October 2026
Registrant name: Vivani Medical, Inc.
Filing date: September 16, 2026
3 metrics
Anticipated Transaction timing
October 2026
Expected month and year for pricing and closing of the Transaction
Registrant name
Vivani Medical, Inc.
Issuer of the Form 8-K
Filing date
September 16, 2026
Date of the Form 8-K communication
Key Terms
Regulation FD, definitive agreement and plan of merger, forward-looking statements, Private Securities Litigation Reform Act of 1995
4 terms
Regulation FD regulatory
"Vivani reports this update under Regulation FD disclosure."
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
definitive agreement and plan of merger financial
"Vivani entered into a definitive agreement and plan of merger among its subsidiary Cortigent, ClearOne, and CLRO Merger Sub."
A definitive agreement and plan of merger is the final, legally binding contract that sets out the exact terms, price, structure, conditions and timeline for combining two companies. It matters to investors because it turns a proposed deal into an obligation that can change ownership stakes, share value and corporate strategy—think of it as signing a sales contract that locks in key terms and makes the likely outcome far more predictable, subject to any closing conditions.
forward-looking statements regulatory
"This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"Forward-looking statements are defined within the meaning of the Private Securities Litigation Reform Act of 1995."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What merger transaction involving VANI is described in this Form 8-K?
Vivani Medical, Inc. describes a definitive agreement and plan of merger among its subsidiary Cortigent, Inc., ClearOne, Inc., and CLRO Merger Sub, Inc., under which Cortigent will merge with and into CLRO Merger Sub and become a wholly owned subsidiary of ClearOne.
When does VANI expect the Cortigent–ClearOne transaction to price and close?
Vivani states that it anticipates the pricing and closing of the Transaction will occur in October 2026, characterizing this as a forward-looking statement subject to risks and uncertainties.
What is Cortigent, Inc.’s role in the VANI transaction with ClearOne?
Cortigent, Inc. is a wholly owned subsidiary of Vivani Medical, Inc. that is expected to merge with and into CLRO Merger Sub, Inc. Following the merger, Cortigent is expected to become a wholly owned subsidiary of ClearOne, Inc.
How is this VANI disclosure treated under the securities laws?
Vivani states that the information in this communication under Regulation FD will not be deemed “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings unless expressly stated.
What risks to the VANI transaction does the company highlight?
Vivani notes that forward-looking statements involve significant risks and uncertainties, including the company’s inability to consummate the Transaction. It refers investors to risk factors discussed in its most recent Form 10-K and subsequent Forms 10-Q filed with the SEC.
Who signed this VANI Form 8-K and in what capacity?
The report is signed on behalf of Vivani Medical, Inc. by Donald Dwyer, who is identified as the company’s Chief Business Officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
